Cite
HARVARD Citation
Sridhar, S. et al. (2022). Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet infectious diseases. 22 (5), pp. 636-648. [Online].